Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02086500 · ClinicalTrials.gov registry record · Phase 3
Study of Tranexamic Acid During Air and Ground Medical Prehospital Transport Trial (STAAMP Trial)
A Phase 3 study of Traumatic Hemorrhage, sponsored by Jason Sperry.
- Completed
- Registry status
- Phase 3
- Development phase
- 903
- Enrollment target
- 1
- Study location
NCT02086500: Completed Phase 3 study of Traumatic Hemorrhage, sponsored by Jason Sperry.
NCT02086500 is a Phase 3 study of Traumatic Hemorrhage that has completed, run by Jason Sperry. The registered enrollment target is 903 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (17% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02086500, a Phase 3 study of Traumatic Hemorrhage, has completed, sponsored by Jason Sperry.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 903 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine if 1 gram of prehospital tranexamic acid given during emergency medical transport to a level 1 trauma center in patients at risk of hemorrhage is associated with lower 30 day mortality.
Primary Outcome
Because not all patients had available data regarding 30-day mortality (patients were discharged and there 30-day outcome was unable to be determined) there may be differences between the 30Day mortality relative to the other outcomes. There were 5 and 4 patients from each arm that did not have 30-day outcome and thus are different.
Conditions Studied
Interventions
- DRUG Tranexamic Acid
- OTHER Saline control
Study Locations (1)
Pennsylvania
- University of Pittsburgh - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 903 participants |
| Start Date | 2015-07 |
| Est. Completion | 2019-11 |
| Phase | Phase 3 |
What the finished NCT02086500 record still lists
NCT02086500 is an interventional study that assigns participants to a tested intervention. The registered 903 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (17% higher).
The record links to 1 condition, with Traumatic Hemorrhage appearing as the primary indexed condition, and to 2 interventions - of which Tranexamic Acid is the first listed.
NCT02086500 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02086500 about?
NCT02086500 is a clinical study titled "Study of Tranexamic Acid During Air and Ground Medical Prehospital Transport Trial (STAAMP Trial)". The purpose of this study is to determine if 1 gram of prehospital tranexamic acid given during emergency medical transport to a level 1 trauma center in patients at risk of hemorrhage is associated with lower 30 day mortality.
What is the current status of trial NCT02086500?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 903 participants. The study started on 2015-07. Estimated completion is 2019-11.
What conditions does trial NCT02086500 study?
This clinical trial studies the following conditions: Traumatic Hemorrhage.
What interventions are being tested in trial NCT02086500?
The interventions under investigation include: Tranexamic Acid (DRUG), Saline control (OTHER).
Who is sponsoring clinical trial NCT02086500?
This trial is sponsored by Jason Sperry, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02086500 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Traumatic Hemorrhage
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02086500's enrollment target sits among peer trials
903 348th of 2000 higher than 1,652 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05769777 · 901 participants · Phase 2
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
- NCT02352116 · 900 participants · NA
Evaluation of Post-PACU Pain Management in Pediatric Surgery
- NCT02414347 · 900 participants
F 18 T807 Tau PET Imaging of Alzheimer's Disease
- NCT02670408 · 900 participants
Diagnostic and Therapeutic Applications of Microarrays in Heart Transplantation
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia